IMGN632 demonstrated an abundant antitumor activity against AML cell lines with or without poor prognostic biomarkers (FLT3-ITD, MDR1, TP53, etc.)and in multiple AML xenograft models, including one model which appeared to be resistant to azacitidine and cytarabine [93, 94]. The gene discussed is TP53; the disease is acute myeloid leukemia.